The Novartis pharmaceutical group says it will buy the Genoptix specialised cancer laboratory in the American state of California for $470 million (SFr452 million).
This content was published on
1 minute
swissinfo.ch and agencies
A statement from Basel-based Novartis on Monday said the acquisition would strengthen its diagnostics operations and diversify its operations further.
The Genoptix board is recommending shareholders accept an offer of $25 per share, which represents a premium of 27 per cent over Friday’s closing price.
Novartis said Genoptix, which specialises in diagnosing cancers in bone marrow, blood and lymph nodes, had sales of $184 million in 2009, employed a staff of 500 and was profitable.
The Swiss group last year bought the Texas-based Alcon eye care company for about $52 billion, including the shares held by the Nestlé food company.
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
United States market proves a legal minefield
This content was published on
Pharmaceutical company Novartis paid $422 million (SFr420 million) in September, the same month that engineering concern ABB handed over $58.3 million. Zurich Financial Services paid $455 million in October, which means that Swiss bank UBS is not alone in losing out on the US market. UBS was handed a penalty of $780 million in a…
This content was published on
At the end of a six-week trial on Monday it awarded compensatory damages of $3.3 million (SFr3.74 million) to 12 women, and punitive damages to a larger group. The class action lawsuit – representing 5,600 women – alleged that the women were discriminated against in the areas of pay, promotions, and pregnancy-related matters. They are…
This content was published on
Joe Jimenez, a 50-year-old American two years into his tenure as CEO of the pharmaceuticals division, was handed the job on Tuesday after chief executive Daniel Vasella announced he was stepping down on February 1. Vasella, 56, has held the job for 14 years and will remain chairman. Chief operating officer Jörg Reinhardt, who had…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.